Novartis AG’s Beovu has matched market-leading ophthalmic therapy Eylea in a new Phase III study, part of its efforts to establish the new less frequently dosed therapy.
The topline results from a Phase III non-inferiority study should pave the way for Beovu (brolucizumab) to add diabetic macular...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?